Equillium (EQ) EBITDA Margin (2023 - 2024)
Equillium (EQ) reported EBITDA Margin of 114.07% for Q4 2024, down 8519.0% year-over-year from 1.35% in Q1 2024, and down 5215.01% quarter-over-quarter from 2.15% in Q3 2024.
Equillium (EQ) EBITDA Margin (2023 - 2024) Analysis & Trends
Equillium (EQ) has 2 years of EBITDA Margin data on file, last reported at 114.07% in Q4 2024.
- EBITDA Margin for Q4 2024 came in at 114.07%, down 8519.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 549.73% (down 53867.0% YoY), and the FY2024 annual result was 18.07%, up 1871.0% from the prior year.
- EBITDA Margin fell to 114.07% in Q4 2024 per EQ's latest filing, from 2.15% in the prior quarter.
- Over five years, EBITDA Margin peaked at 2.14% in Q2 2024 and troughed at 114.07% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Equillium | 293.17 Mn | 232.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -114.07% |
| Sep 30, 2024 | -2.15% |
| Jun 30, 2024 | 2.14% |
| Mar 31, 2024 | -22.93% |
| Dec 31, 2023 | -28.88% |
| Sep 30, 2023 | -40.50% |
| Jun 30, 2023 | -36.26% |
| Mar 31, 2023 | -41.80% |